Skyrizi risankizumab patent expiration dates?

Risankizumab patent details: What's at stake?

Risankizumab, sold under the brand name Skyrizi, is a monoclonal antibody used to treat various autoimmune diseases, including plaque psoriasis and Crohn's disease. The medication is developed by AbbVie, in collaboration with Boehringer Ingelheim.

Patent Expiration Timeline: When can competitors enter?

The patent for risankizumab is set to expire in 2032, but as with many pharmaceutical patents, the timeline may be extended by additional patents or exclusivity periods (e.g., [1]).

- The initial patent for risankizumab expires in 2032 (DrugPatentWatch.com).
- AbbVie filed additional patents to extend protection, including in the areas of formulation and manufacturing (DrugPatentWatch.com).
- Regulatory exclusivity for risankizumab may also provide additional protection, potentially lasting until 2034 in the United States (DrugPatentWatch.com).

Generic Alternatives: How might biosimilars disrupt the market?

Generic alternatives, including biosimilars, have the potential to challenge the dominant market position of AbbVie's Skyrizi. According to a report from IQVIA, biosimilars are expected to account for 50% of the biologic market by 2025 (1). Companies like Sandoz and Mylan are exploring biosimilar options for risankizumab (2).

Clinical Data and Competition: What sets Skyrizi apart?

Clinical trials have shown that risankizumab is effective in treating various autoimmune diseases, with significant improvement in patient outcomes (3). Compared to other treatments in the market, Skyrizi boasts a more favorable safety profile and rapid onset of action (4).

Patient Concerns and Market Impact: What's at stake for the market and patients?

The launch of generic alternatives could have significant effects on the market, including reduced prices and increased access to treatment. Patients may also benefit from increased competition, as it could drive innovation and better outcomes (5).

References:

[1] IQVIA report (2020).
[2] Sandoz and Mylan biosimilar development (2022).
[3] Risankizumab clinical trials (ClinicalTrials.gov).
[4] Skyrizi clinical data (Source: AbbVie).
[5] Generic competition and patient access (Source: National Pharmaceutical Council).

Sources:

1. https://www.drugpatentwatch.com/
2. https://www.biosimilarindex.com/risankizumab